Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
Schwartz
Robert S
RS
Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.
D000077284:Abciximab; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D023921:Coronary Stenosis / Q000175:diagnosis / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008833:Microcirculation / Q000000981:diagnostic imaging / Q000187:drug effects*; D009203:Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D003402:Creatine Kinase; D000077284:Abciximab